Finerenone in Hypertensive Non-Diabetic Chronic Kidney Disease: Evidence from the FIND-CKD Subgroup Analysis

Highlight

• Finerenone slows estimated glomerular filtration rate (eGFR) decline in hypertensive non-diabetic chronic kidney disease (CKD).
• It significantly reduces the composite kidney-cardiovascular outcome including kidney failure and cardiovascular events.
• The benefits occur regardless of baseline systolic blood pressure levels.
• Finerenone’s safety is acceptable, with hyperkalaemia being the primary adverse event, rarely leading to treatment discontinuation.

Study Background